Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP).

Bainbridge TW, Dunshee DR, Kljavin NM, Skelton NJ, Sonoda J, Ernst JA.

Sci Rep. 2017 Oct 2;7(1):12524. doi: 10.1038/s41598-017-12900-8.

2.

Stem cell plasticity enables hair regeneration following Lgr5+ cell loss.

Hoeck JD, Biehs B, Kurtova AV, Kljavin NM, de Sousa E Melo F, Alicke B, Koeppen H, Modrusan Z, Piskol R, de Sauvage FJ.

Nat Cell Biol. 2017 Jun;19(6):666-676. doi: 10.1038/ncb3535. Epub 2017 May 29.

PMID:
28553937
3.

Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21.

Dunshee DR, Bainbridge TW, Kljavin NM, Zavala-Solorio J, Schroeder AC, Chan R, Corpuz R, Wong M, Zhou W, Deshmukh G, Ly J, Sutherlin DP, Ernst JA, Sonoda J.

J Biol Chem. 2016 Mar 11;291(11):5986-96. doi: 10.1074/jbc.M115.710582. Epub 2016 Jan 21.

4.

Requirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinoma.

Chen H, Lee J, Kljavin NM, Haley B, Daemen A, Johnson L, Liang Y.

Genes Cancer. 2015 Mar;6(3-4):106-18.

5.

Homeostatic IL-23 receptor signaling limits Th17 response through IL-22-mediated containment of commensal microbiota.

Shih VF, Cox J, Kljavin NM, Dengler HS, Reichelt M, Kumar P, Rangell L, Kolls JK, Diehl L, Ouyang W, Ghilardi N.

Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13942-7. doi: 10.1073/pnas.1323852111. Epub 2014 Sep 8.

6.

Comparative oncogenomics identifies PSMB4 and SHMT2 as potential cancer driver genes.

Lee GY, Haverty PM, Li L, Kljavin NM, Bourgon R, Lee J, Stern H, Modrusan Z, Seshagiri S, Zhang Z, Davis D, Stokoe D, Settleman J, de Sauvage FJ, Neve RM.

Cancer Res. 2014 Jun 1;74(11):3114-26. doi: 10.1158/0008-5472.CAN-13-2683. Epub 2014 Apr 22.

7.

Lgr5+ stem cells are indispensable for radiation-induced intestinal regeneration.

Metcalfe C, Kljavin NM, Ybarra R, de Sauvage FJ.

Cell Stem Cell. 2014 Feb 6;14(2):149-59. doi: 10.1016/j.stem.2013.11.008. Epub 2013 Dec 12.

8.

Oncogenic ERBB3 mutations in human cancers.

Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA, Janakiraman V, Scholz RP, Bowman KK, Lorenzo M, Li H, Wu J, Yuan W, Peters BA, Kan Z, Stinson J, Mak M, Modrusan Z, Eigenbrot C, Firestein R, Stern HM, Rajalingam K, Schaefer G, Merchant MA, Sliwkowski MX, de Sauvage FJ, Seshagiri S.

Cancer Cell. 2013 May 13;23(5):603-17. doi: 10.1016/j.ccr.2013.04.012. Erratum in: Cancer Cell. 2014 Apr 14;25(4):543-4.

9.

A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.

Bentley C, Jurinka SS, Kljavin NM, Vartanian S, Ramani SR, Gonzalez LC, Yu K, Modrusan Z, Du P, Bourgon R, Neve RM, Stokoe D.

Biochem J. 2013 Jun 1;452(2):313-20. doi: 10.1042/BJ20121578.

PMID:
23496764
10.

Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.

Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, Stawiski E, Lee B, Lin J, Li H, Lorenzo MN, Yuan W, Guillory J, Jackson M, Rondon J, Franke Y, Bowman KK, Sagolla M, Stinson J, Wu TD, Wu J, Stokoe D, Stern HM, Brandhuber BJ, Lin K, Skelton NJ, Seshagiri S.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19368-73. doi: 10.1073/pnas.1204384109. Epub 2012 Nov 7.

11.

Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.

Yuan W, Stawiski E, Janakiraman V, Chan E, Durinck S, Edgar KA, Kljavin NM, Rivers CS, Gnad F, Roose-Girma M, Haverty PM, Fedorowicz G, Heldens S, Soriano RH, Zhang Z, Wallin JJ, Johnson L, Merchant M, Modrusan Z, Stern HM, Seshagiri S.

Oncogene. 2013 Jan 17;32(3):318-26. doi: 10.1038/onc.2012.53. Epub 2012 Feb 27.

12.

Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice.

Cox JH, Kljavin NM, Ota N, Leonard J, Roose-Girma M, Diehl L, Ouyang W, Ghilardi N.

Mucosal Immunol. 2012 Jan;5(1):99-109. doi: 10.1038/mi.2011.54. Epub 2011 Nov 16.

PMID:
22089030
13.

IL-27 promotes T cell-dependent colitis through multiple mechanisms.

Cox JH, Kljavin NM, Ramamoorthi N, Diehl L, Batten M, Ghilardi N.

J Exp Med. 2011 Jan 17;208(1):115-23. doi: 10.1084/jem.20100410. Epub 2010 Dec 20.

14.

IL-27 supports germinal center function by enhancing IL-21 production and the function of T follicular helper cells.

Batten M, Ramamoorthi N, Kljavin NM, Ma CS, Cox JH, Dengler HS, Danilenko DM, Caplazi P, Wong M, Fulcher DA, Cook MC, King C, Tangye SG, de Sauvage FJ, Ghilardi N.

J Exp Med. 2010 Dec 20;207(13):2895-906. doi: 10.1084/jem.20100064. Epub 2010 Nov 22.

15.

Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.

Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, Kan Z, Dbouk HA, Peters BA, Waring P, Dela Vega T, Kenski DM, Bowman KK, Lorenzo M, Li H, Wu J, Modrusan Z, Stinson J, Eby M, Yue P, Kaminker JS, de Sauvage FJ, Backer JM, Seshagiri S.

Cancer Cell. 2009 Dec 8;16(6):463-74. doi: 10.1016/j.ccr.2009.10.016.

16.

Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.

Jaiswal BS, Janakiraman V, Kljavin NM, Eastham-Anderson J, Cupp JE, Liang Y, Davis DP, Hoeflich KP, Seshagiri S.

PLoS One. 2009 May 27;4(5):e5717. doi: 10.1371/journal.pone.0005717.

17.

Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.

Polson AG, Calemine-Fenaux J, Chan P, Chang W, Christensen E, Clark S, de Sauvage FJ, Eaton D, Elkins K, Elliott JM, Frantz G, Fuji RN, Gray A, Harden K, Ingle GS, Kljavin NM, Koeppen H, Nelson C, Prabhu S, Raab H, Ross S, Slaga DS, Stephan JP, Scales SJ, Spencer SD, Vandlen R, Wranik B, Yu SF, Zheng B, Ebens A.

Cancer Res. 2009 Mar 15;69(6):2358-64. doi: 10.1158/0008-5472.CAN-08-2250. Epub 2009 Mar 3. Erratum in: Cancer Res. 2010 Feb 1;70(3):1275. Slaga, Dion S [added].

18.

Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells.

Batten M, Kljavin NM, Li J, Walter MJ, de Sauvage FJ, Ghilardi N.

J Immunol. 2008 Mar 1;180(5):2752-6.

19.

Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells.

Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, Lee J, de Sauvage FJ, Ghilardi N.

Nat Immunol. 2006 Sep;7(9):929-36. Epub 2006 Aug 13.

PMID:
16906167
20.

CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens.

Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren Campagne M.

Cell. 2006 Mar 10;124(5):915-27.

Supplemental Content

Loading ...
Support Center